Fig. 3

Beneficial effect of artemether plus RRx-001 treatment in leukocyte adhering and rolling in pial venules from late-stage ECM mice. Groups are displayed as follows: untreated Plasmodium berghei ANKA infected mice (black), PbA infected mice treated with RRx-001 (IV at 10 mg/kg, red), PbA infected mice treated with artemether (IP at 50 mg/kg blue) and PbA infected mice treated with 10 mg/kg IV of RRx-001 plus 50 mg/kg IP of artemether (red with blue border). a. Adhering leukocytes. Leukocyte adhesion in venules was measured (Day 9). b. Rolling leukocytes. Leukocyte rolling in venules was measured (Day 9). c. Haematocrit after infection. Mice were either left untreated (n = 7; white quare) or were treated with RRx-001 (IV at 10 mg/kg; n = 7 mice; red circle) or artemether alone (IP at 50 mg/kg; n = 7, blue diamond), or 10 mg/kg IV of RRx-001 plus 50 mg/kg IP of artemether (n = 7, red circle with blue border). Haematocrit was measured from samples collected from the tail vein. Hct were measured at the same time points for all groups. The points were artificially displaced horizontally for clarity